Clinical trials: Vein Occlusion
Chronic Venous Disorder, Venous Outflow Obstruction
Clinical Outcomes of IVUS-guided Stenting Using the Boston Scientific Vici® Venous Stent System in Treating Patients With Chronic Non-malignant Iliofemoral Vein Obstruction
The APAC VICI Study is a prospective, non-randomized, multicenter, single-arm study. The purpose of this study is to evaluate the clinical results of using the Boston Scientifc's Vici Venous Stent (Vici stent) to treat…
- Conditions
- Chronic Venous Disorder, Venous Outflow Obstruction, Systemic Vein Outflow of Iliofemoral Vein
- Trial name
- APAC VICI (NCT04856592)
- Testing
- Boston Scientific Vici® Venous Stent System, Boston Scientific Opticross 35 Peripheral Imaging Catheter (OC35 catheter)
- Sponsor
- Boston Scientific Corporation
Healthy
Effects of Miconazole on Blood Flow
This study will investigate the effect of the drug miconazole on blood vessel dilation. Miconazole stops production of EDHF, a substance that causes arteries to dilate. EDHF is produced by the cells that line blood vessels.
- Trial name
- NCT00004575
- Testing
- Miconazole, L-NMMA, Bradykinin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Central Retinal Vein Occlusion
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy. It induces circulatory slowdown and blood stasis, which can appear as retinal hemorrhages.
- Trial name
- PULSOV (NCT04793100)
- Testing
- Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)
The primary objective is to demonstrate the non-inferiority of bevacizumab in the treatment of patients with macular edema secondary to a retinal vein occlusion (branch or central) as determined by the change in best-corrected…
- Trial name
- BRVO (NCT01635803)
- Testing
- Bevacizumab, Ranibizumab
- Where
- Netherlands
- Volunteers
- 296 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)